You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →
Clene Inc. announces a registered direct offering of $4 million. The offering involves 1,219,513 shares priced at $3.28 each and is led by Chairman David Matlin and other existing shareholders.
PUBLIC · CLNNSep 15, 2026•1 day ago
Amount Raised
$4 Million
Round Type
Seed
Salt Lake CityBiotechnologyTherapeuticsPharmaceuticalBiopharma
Investors
Kensington Capital HoldingsDavid Matlin
Description
Clene Inc. has priced a registered direct offering of 1,219,513 shares at $3.28 per share to existing shareholders, raising a total of $4 million. The offering is expected to close on September 17, 2026. Proceeds will support operations through mid-first quarter 2027 and fund various corporate purposes
Company Information
Company
Clene Nanomedicine
Location
6550 SOUTH MILLROCK DRIVE, SUITE G50
Salt Lake City, Utah, United States
About
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc.
Don't miss Clene Nanomedicine's next move
Get an email the moment Clene Nanomedicine raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contact
Predictive Intelligence
Strategic
ML-powered predictions for Clene Nanomedicine's next move
Salt Lake CityBiotechnologyTherapeuticsPharmaceuticalBiopharma